Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Oculis Holding AG

OCS ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: STRONG BUY

Last Close

$12.16

▼ -0.08%

Market Cap $750.66M · Vol 36.45K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$750.66M

Small Cap

Div Yield

N/A

EPS Growth

+20.48%

YoY

RSI (14)

28.36

Momentum

Beta

0.25

vs Market

52W High

$34.12

64.36% below

52W Low

$10.53

15.48% above

Volume

36.45K

Avg 61.24K

P/B

4.74

Price-to-book

ROE

-73.45%

Return on equity

Free Float

83.90%

Public shares

Shariah Compliance8 STANDARDS

✗ Oculis Holding AG (OCS) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does OCS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.73%

-4.10%

+13.54%

-54.90%

YTD

-39.11%

-29.38%

-5.37%

+25.10%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-124,898,397.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-73.45%
ROA · ROIC	-55.65% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	4.74
P/FCF	N/A
EPS Growth	+20.48%
Outstanding Shares	61.73M

Technical Indicators

50-Day SMA	$12.56
200-Day SMA	$21.01
RSI (14)	28.36
Beta	0.25
52-Week High	$34.12
52-Week Low	$10.53

Volume Today	36.45K
Avg Daily Volume (30D)	61.24K
Relative Volume	0.60x
Volatility (10D)	23.11
Volatility (30D)	29.34
Free Float	83.90%

Analyst Consensus

STRONG BUY

Current Price $12.16

Mean Target $37.56

52W Low$10.53 52W High$34.12

Current

Target

$10.53 $34.12

Current Analyst target

+208.85% upside potential · 10 analysts

Identifiers

ExchangeNasdaq

FIGIBBG01BJ1BJ07

ISINCH1242303498

CountrySwitzerland

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 5, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -0.82% RVMD Revolution Medicines Inc -1.29% ONC BeOne Medicines AG -1.89% 068270.KS Celltrion Inc +0.53% ABVX Abivax SA +3.62%

Company Profile

Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.